Chi, Kim N.
BC Cancer Agency
22 papers on CoChatORCID 0000-0002-3782-7226
Most cited papers
- Verified
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine
Prostate Cancer Treatment and ResearchBone health and treatments
Cited by 5,735
- Verified
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 4,586
- Verified
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 4,407
- Verified
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine
Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research
Cited by 2,864
- Verified
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine
PARP inhibition in cancer therapyProstate Cancer Treatment and Research
Cited by 2,323
- Verified
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., et al. (2019) · New England Journal of Medicine
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 1,633
- Verified
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2019) · New England Journal of Medicine
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 1,564
- Verified
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., et al. (2018) · Journal of Clinical Oncology
Prostate Cancer Treatment and ResearchNeuroblastoma Research and Treatments
Cited by 810
- Verified
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine
PARP inhibition in cancer therapyProstate Cancer Treatment and Research
Cited by 792
- Verified
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., et al. (2018) · Cell
Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics
Cited by 733
- Verified
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
Halabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Hussain, M., et al. (2016) · Journal of Clinical Oncology
Prostate Cancer Treatment and ResearchBone health and treatments
Cited by 461
- Verified
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., et al. (2024) · The Lancet
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications
Cited by 362
- Verified
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology
Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy
Cited by 355
- Verified
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
Fonseca, N. M., Maurice-Dror, C., Herberts, C., Tu, W., Fan, W., Murtha, A. J., Kollmannsberger, C., Kwan, E. M., Parekh, K., Schönlau, E., et al. (2024) · Nature Communications
Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics
Cited by 145
- Verified
Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021
Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., et al. (2022) · European Urology
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 130
- Verified
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Fizazi, K., Herrmann, K., Krause, B. J., Rahbar, K., Chi, K. N., Morris, M. J., Sartor, O., Tagawa, S. T., Kendi, A. T., Vogelzang, N., et al. (2023) · The Lancet Oncology
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications
Cited by 125
- Verified
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer
Lim, E. A., Schweizer, M. T., Chi, K. N., Aggarwal, R., Agarwal, N., Gulley, J., Attiyeh, E., Greger, J., Wu, S., Jaiprasart, P., et al. (2023) · Clinical Genitourinary Cancer
Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers
Cited by 62
- Verified
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
Chi, K. N., Armstrong, A. J., Krause, B. J., Herrmann, K., Rahbar, K., de Bono, J. S., Adra, N., Garje, R., Michalski, J. M., Kempel, M. M., et al. (2024) · European Urology
Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research
Cited by 37
- Verified
Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection
Park, E. S., Yan, J. P., Ang, R. A., Lee, J. H., Deng, X., Duffy, S. P., Beja, K., Annala, M., Black, P. C., Chi, K. N., et al. (2018) · Lab on a Chip
Cancer Genomics and DiagnosticsSingle-cell and spatial transcriptomics
Cited by 34
- Verified
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Halabi, S., Yang, Q., Roy, A., Luo, B., Araujo, J. C., Logothetis, C., Sternberg, C. N., Armstrong, A. J., Carducci, M. A., Chi, K. N., et al. (2023) · Journal of Clinical Oncology
Prostate Cancer Treatment and ResearchBone health and treatments
Cited by 30
- Verified
Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review
Maurice Dror, C., Chi, K. N., & Khalaf, D. J. (2021) · Translational Andrology and Urology
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 14
- Verified
Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.
Krause, B. J., Chi, K. N., Sartor, A. O., Fizazi, K., Morris, M. J., De Bono, J. S., Tagawa, S. T., Herrmann, K., Kurth, J., Eiber, M., et al. (2023) · Journal of Clinical Oncology
Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications
Cited by 11
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free